Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA grants breakthrough therapy status for Novartis' crizanlizumab to prevent vaso-occlusive crises in sickle cell disease

firstwordpharmaJanuary 09, 2019

Tag: Novartis , FDA , Breakthrough Therapy , Novartis

PharmaSources Customer Service